LMR 8

Yves Laure Pimentel · 70問 · 2年前

通報

問題一覧

Macrocytes tend to settle more rapidly than microcytes

ERTHROCYTE SEDIMENTATION RATE

ERTHROCYTE SEDIMENTATION RATE Macrocytes tend to settle more rapidly than ?

microcytes

ERTHROCYTE SEDIMENTATION RATE Anisocytosis and poikilocytosis: ? ESR

falsely lower

ERTHROCYTE SEDIMENTATION RATE : more rapid sedimentation rate

Agglutination

ERTHROCYTE SEDIMENTATION RATE In severe anemia: ESR IS

MARKEDLY INCREASED

ERTHROCYTE SEDIMENTATION RATE In ?: ESR IS MARKEDLY INCREASED

severe anemia

SUGAR WATER TEST .ANTICOAGULATED? whole blood

Citrated whole blood

SUGAR WATER TEST .In ?, the hemolysis may be slightly increased in PNH negative specimens

anemia

SUGAR WATER TEST . Use of ? blood may cause positive results due to the hemolysis of traumatized RBCs

defibrinated

SUGAR WATER TEST Test should be performed WITHIN ? of obtaining the specimen

2 HOURS

SUCROSE HEMOLYSIS TEST ANTICOAGULATED whole blood

Citrated whole blood

SUCROSE HEMOLYSIS TEST ncreased hemolysis (<10%) may be found in ? or ?

leukemia or myelosclerosis

SUCROSE HEMOLYSIS TEST ncreased hemolysis (?%) may be found in leukemia or myelosclerosis

<10

SUCROSE HEMOLYSIS TEST : 10% to 80% hemolysis

PNH

SUCROSE HEMOLYSIS TEST PNH: % hemolysis

10% to 80% hemolysis

ACID SERUM TEST SPECIMEN USED?

Whole blood defibrinated

ACID SERUM TEST Thyroxine (µg/dL to nmol/L)

12.9

ACID SERUM TEST (µg/dL to nmol/L) 12.9

Thyroxine

: HORIZONTAL, ABSCISSA, INDEPENDENT VARIABLES

X-axis

X-axis:

HORIZONTAL, ABSCISSA, INDEPENDENT VARIABLES

: VERTICAL, ORDINATE, DEPENDENT VARIABLES

Y-axis

VERTICAL, ORDINATE, DEPENDENT VARIABLES

UREA: ?: diacetyl [ inexpensive, lacks specificity]

Colorimetric

UREA: ?: NH3 formation [greater specificity, more expensive]

Enzymatic

CREATININE: ? [simple, nonspecific]

Colorimetric: end point

CREATININE: Colorimetric: ? [rapid, increased specificity]

kinetic

CREATININE: ? [measure ammonia colorimetrically or with ion-selective electrode]

Enzymatic

[problems with turbidity, several common drugs interfere]

URIC ACID: Colorimetric

URIC ACID: Enzymatic: ? [need special instrumentation and optical cells]

URIC ACID: Enzymatic: ? [interference by reducing substances]

H2O2

. Constituents of a number of common foods, including BANANAS, VANILLA, TEA AND COFFEE, may react in the test for ?

HMMA

is also VMA.

HMMA 4-Hydroxy-3-Methoxymandelic acid (HMMA)

Third Taenia:

Taenia asiatica or the Taiwan Taenia

: Taenia asiatica or the Taiwan Taenia

Third Taenia

Fungal elements

fluoresce green with acridine orange

Reporting of normal urine crystals: reported as

rare, few, moderate, or many per hp

Reporting of normal urine ?: reported as rare, few, moderate, or many per hp

crystals

Abnormal crystals may be ? and reported?

averaged , per lpf

Reagent for APT test:

1% NaOH

Infective stage of Leishmania to man:

PROMASTIGOTE

Infective stage of Trypanosoma to man:

TRYPOMASTIGOTE

Infective stage of Plasmodia to man:

SPOROZOITES

Eosinophilic meningoencephalitis:

ANGIOSTRONGYLUS CANTONENSIS

: ANGIOSTRONGYLUS CANTONENSIS

Eosinophilic meningoencephalitis

When an accident involving electrical shock occurs, the ? MUST BE REMOVED IMMEDIATELY.

ELECTRICAL SOURCE

: external urinary opening

URINARY MEATUS

: greater than 2.5 L/day in adults

POLYURIA

POLYURIA: greater than ?day in adults

2.5 L/

: less than 400 mL/day in adults

OLIGURIA

OLIGURIA: less than ? in adults

400 mL/day

?COLOR? specimen caused by the administration of phenazopyridine (brand name Pyridium) or azo-gantrisin compounds to people who have urinary tract infections [drug for UTI: orange and viscous urine]

Yellow-orange

Yellow-orange specimen caused by the administration of ? (brand name Pyridium) or azo-gantrisin compounds to people who have urinary tract infections [drug for UTI: orange and viscous urine]

phenazopyridine

Yellow-orange specimen caused by the administration of phenazopyridine (brand name ?) or azo-gantrisin compounds to people who have urinary tract infections [drug for UTI: orange and viscous urine]

Pyridium

Yellow-orange specimen caused by the administration of phenazopyridine (brand name Pyridium) or ? compounds to people who have urinary tract infections [drug for UTI: orange and viscous urine]

azo-gantrisin

Yellow-orange specimen caused by the administration of phenazopyridine (brand name Pyridium) or azo-gantrisin compounds to people who have urinary tract infections [drug for UTI: ?]

orange and viscous urine

? tablets contain copper sulfate, sodium carbonate, sodium citrate, and sodium hydroxide

CLINITEST

CLINITEST tablets contain

SAD (SOD) HIGH (HY) CA, CI copper sulfate, sodium carbonate, sodium citrate, and sodium hydroxide

provides sodium nitroprusside, glycine, disodium phosphate, and lactose in tablet form. The addition of lactose gives better color differentiation.

ACETEST

? tablets are hygroscopic; if the specimen is not completely absorbed within 30 seconds, a new tablet should be used

Acetest

Acetest tablets are ?; if the specimen is not completely absorbed within 30 seconds, a new tablet should be used

hygroscopic

Acetest tablets are hygroscopic; if the specimen is not completely absorbed within ? seconds, a new tablet should be used

coagulates at temperatures between 40°C and 60°C and dissolves when the temperature reaches 100°C.

Bence Jones protein

Bence Jones protein coagulates at temperatures between ? and dissolves when the temperature reaches 100°C.

40°C and 60°C

Bence Jones protein coagulates at temperatures between 40°C and 60°C and dissolves when the temperature reaches ?

100°C.

Automated reagent strip readers:

REFLECTANCE PHOTOMETRY

have a tendency to locate NEAR THE EDGES OF THE COVER SLIP

Casts

MICROSCOPIC READING Squamous epithelial cells:

Rare, few, moderate, or many per LPF

MICROSCOPIC READING Transitional epithelial cells:

Rare, few, moderate, or many per HPF

MICROSCOPIC READING RTE CELLS:

AVERAGE NUMBER PER 10 HPFS

: Acid-albumin and the CTAB tests (+) thick, white turbidity

MUCOPOLYSACCHARIDES

MUCOPOLYSACCHARIDES: Acid-albumin and the CTAB tests (+) ? RESULTS

thick, white turbidity

MUCOPOLYSACCHARIDES: Metachromatic staining spot test:

BLUE SPOT

Very slight amount of ?: PINK CSF

OXYHEMOGLOBIN

Very slight amount of OXYHEMOGLOBIN: ? CSF

PINK

Conversion of oxyhemoglobin to unconjugated bilirubin:

YELLOW CSF

Conversion of ?: YELLOW CSF

oxyhemoglobin to unconjugated bilirubin

Heavy hemolysis:

ORANGE CSF

: ORANGE CSF

Heavy hemolysis

Red or brown seminal fluid:

BLOOD

Normal appearance of gastric fluid:

PALE GRAY with mucus

Amniotic fluid OD ?: When BILIRUBIN is present, a rise in OD is seen at ? nm because this is the wavelength of maximum bilirubin absorption.

450

: 0–10 bacteria/hpf

Rare

Rare: ? bacteria/hpf

0–10

Few: ? bacteria/hpf

10–50

: 10–50 bacteria/hpf

Few

: 50–200 bacteria/hpf

Moderate

Moderate: ?bacteria/hpf

50–200

: >200 bacteria/hpf

Many

Many: ? bacteria/hpf

>200

First layer of spun hematocrit:

FATTY LAYER

Second layer of spun hematocrit:

PLASMA

Third layer of spun hematocrit:

BUFFY COAT

Bottom layer of spun hematocrit:

PACKED CELLS

Patients with CML negative for the Philadelphia chromosome:

POOR PROGNOSIS

>11 x 10 9th/L

LEUKOCYTOSIS

>11 x 10 9th/L

Forward light scatter:

CELL SIZE

Side light scatter:

CELL GRANULARITY

: helmet cells/with horn-like projections

KERATOCYTES

100

: most specific antibody for SLE

ANTI-dsDNA

other names parasitology

other names parasitology

70問 • 2年前

Yves Laure Pimentel · 111問 · 2年前

PARASITOLOGY

PARASITOLOGY

111問 • 2年前

Yves Laure Pimentel · 64問 · 2年前

HTMLBE

HTMLBE

64問 • 2年前

Yves Laure Pimentel · 61問 · 2年前

CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

61問 • 2年前

Yves Laure Pimentel · 69問 · 2年前

HISTOPATHOLOGY

HISTOPATHOLOGY

69問 • 2年前

CC-2 SPECTROPHOTOMETRY

CC-2 SPECTROPHOTOMETRY

Yves Laure Pimentel · 41問 · 2年前

CC-3 ELECTROPHORESIS

CC-3 ELECTROPHORESIS

41問 • 2年前

Yves Laure Pimentel · 87問 · 2年前

AUBF LAB SAFETY

AUBF LAB SAFETY

87問 • 2年前

CSF 1

CSF 1

Yves Laure Pimentel · 82問 · 2年前

CSF 2

CSF 2

82問 • 2年前

SEMEN 1

SEMEN 1

Yves Laure Pimentel · 7問 · 2年前

SEMEN 2

SEMEN 2

7問 • 2年前

SYNOVIAL FLUID 1

SYNOVIAL FLUID 1

Yves Laure Pimentel · 6問 · 2年前

SYNOVIAL FLUID 2

SYNOVIAL FLUID 2

6問 • 2年前

Yves Laure Pimentel · 25問 · 2年前

SEROUS FLUID

SEROUS FLUID

25問 • 2年前

Yves Laure Pimentel · 44問 · 2年前

PLEURAL FLUID

PLEURAL FLUID

44問 • 2年前

Yves Laure Pimentel · 18問 · 2年前

PERICARDIAL FLUID

PERICARDIAL FLUID

18問 • 2年前

Yves Laure Pimentel · 30問 · 2年前

PERITONEAL FLUID/ ASCITIC FLUID

PERITONEAL FLUID/ ASCITIC FLUID

30問 • 2年前

Yves Laure Pimentel · 92問 · 2年前

AMNIOTIC FLUID

AMNIOTIC FLUID

92問 • 2年前

Yves Laure Pimentel · 80問 · 2年前

FECALYSIS

FECALYSIS

80問 • 2年前

Yves Laure Pimentel · 89問 · 2年前

OTHER BODY FLUIDS

OTHER BODY FLUIDS

89問 • 2年前

Yves Laure Pimentel · 86問 · 2年前

MTLBE- SUHO NOTES

MTLBE- SUHO NOTES

86問 • 2年前

Yves Laure Pimentel · 35問 · 2年前

MTLBE..

MTLBE..

35問 • 2年前

Yves Laure Pimentel · 19問 · 1年前

CC- CHROMATOGRAPHY

CC- CHROMATOGRAPHY

19問 • 1年前

Yves Laure Pimentel · 14問 · 1年前

CC-OSMOMETRY

CC-OSMOMETRY

14問 • 1年前

Yves Laure Pimentel · 43問 · 1年前

CC-ELECTROCHEMISTRY TECHNIQUES

CC-ELECTROCHEMISTRY TECHNIQUES

43問 • 1年前

Yves Laure Pimentel · 49問 · 2年前

CC- CARBOHYDRATES

CC- CARBOHYDRATES

49問 • 2年前

Yves Laure Pimentel · 97問 · 2年前

CC- DIABETES MELLITUS

CC- DIABETES MELLITUS

97問 • 2年前

Yves Laure Pimentel · 57問 · 2年前

MAJOR LIPOPROTEINS

MAJOR LIPOPROTEINS

57問 • 2年前

Yves Laure Pimentel · 63問 · 2年前

MINOR LIPOPROTEINS

MINOR LIPOPROTEINS

63問 • 2年前

Yves Laure Pimentel · 37問 · 2年前

PROTEINS

PROTEINS

37問 • 2年前

Yves Laure Pimentel · 91問 · 2年前

PLASMA PROTEINS 1

PLASMA PROTEINS 1

91問 • 2年前

Yves Laure Pimentel · 98問 · 2年前

PLASMA PROTEINS 2 (ALPHA 2 REGION)

PLASMA PROTEINS 2 (ALPHA 2 REGION)

98問 • 2年前

Yves Laure Pimentel · 61問 · 2年前

MISCELLANEOUS PROTEINS

MISCELLANEOUS PROTEINS

61問 • 2年前

Liver Function Test 1

Liver Function Test 1

Yves Laure Pimentel · 96問 · 2年前

Liver Function Test 2

Liver Function Test 2

96問 • 2年前

Yves Laure Pimentel · 33問 · 2年前

TUMOR MARKERS

TUMOR MARKERS

33問 • 2年前

Yves Laure Pimentel · 41問 · 2年前

KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

41問 • 2年前

Yves Laure Pimentel · 17問 · 2年前

GLYCOGEN STORAGE DISEASES

GLYCOGEN STORAGE DISEASES

17問 • 2年前

Yves Laure Pimentel · 14問 · 2年前

LIPID STORAGE DISEASES

LIPID STORAGE DISEASES

14問 • 2年前

Yves Laure Pimentel · 71問 · 2年前

PROTEINS

PROTEINS

71問 • 2年前

Yves Laure Pimentel · 7問 · 2年前

QUICK FIRE- ELECTRODES

QUICK FIRE- ELECTRODES

7問 • 2年前

Yves Laure Pimentel · 10問 · 2年前

ELECTROLYTES

ELECTROLYTES

10問 • 2年前

Yves Laure Pimentel · 27問 · 2年前

DRUGS

DRUGS

27問 • 2年前

Yves Laure Pimentel · 12問 · 2年前

TOXIC AGENTS:

TOXIC AGENTS:

12問 • 2年前

HEMATOLOGY 1 (HEMATOPOIESIS 1)

HEMATOLOGY 1 (HEMATOPOIESIS 1)

Yves Laure Pimentel · 29問 · 2年前

HEMATOLOGY (HEMATOPOIESIS 2)

HEMATOLOGY (HEMATOPOIESIS 2)

29問 • 2年前

Yves Laure Pimentel · 25問 · 2年前

hema diseases

hema diseases

25問 • 2年前

Yves Laure Pimentel · 43問 · 2年前

AML

AML

43問 • 2年前

Yves Laure Pimentel · 71問 · 2年前

GLOBIN SYNTHESIS

GLOBIN SYNTHESIS

71問 • 2年前

Yves Laure Pimentel · 31問 · 2年前

HEMATOLOGY REFERENCE RANGES

HEMATOLOGY REFERENCE RANGES

31問 • 2年前

Yves Laure Pimentel · 34問 · 2年前

DISORDERS OF PRIMARY HEMOSTASIS

DISORDERS OF PRIMARY HEMOSTASIS

34問 • 2年前

Yves Laure Pimentel · 37問 · 2年前

PLATELET DISORDERS

PLATELET DISORDERS

37問 • 2年前

CHARACTERISTICS OF CLOTTING FACTORS

CHARACTERISTICS OF CLOTTING FACTORS

Yves Laure Pimentel · 12問 · 2年前

4. CLASSIFICATION OF MACROPHAGE

4. CLASSIFICATION OF MACROPHAGE

12問 • 2年前

Yves Laure Pimentel · 39問 · 2年前

3. NATURAL OR INNATE IMMUNITY

3. NATURAL OR INNATE IMMUNITY

39問 • 2年前

Yves Laure Pimentel · 55問 · 2年前

5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

55問 • 2年前

Yves Laure Pimentel · 37問 · 2年前

6. PHAGOCYTOSIS Chemotaxis

6. PHAGOCYTOSIS Chemotaxis

37問 • 2年前

Yves Laure Pimentel · 44問 · 2年前

8. NATURE OF ANTIGEN

8. NATURE OF ANTIGEN

44問 • 2年前

Yves Laure Pimentel · 50問 · 2年前

9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

50問 • 2年前

Yves Laure Pimentel · 69問 · 2年前

1. HISTORY

1. HISTORY

69問 • 2年前

Yves Laure Pimentel · 38問 · 2年前

2. TYPES OF IMMUNITY

2. TYPES OF IMMUNITY

38問 • 2年前

Yves Laure Pimentel · 21問 · 2年前

7. PHAGOCYTOSIS Engulfment and Digestion

7. PHAGOCYTOSIS Engulfment and Digestion

21問 • 2年前

Yves Laure Pimentel · 15問 · 2年前

8. PHAGOCYTOSIS EXOCYTOSIS

8. PHAGOCYTOSIS EXOCYTOSIS

15問 • 2年前

Yves Laure Pimentel · 32問 · 2年前

10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

32問 • 2年前

Yves Laure Pimentel · 30問 · 2年前

11. TRANSPLANTATION IMMUNOLOGY

11. TRANSPLANTATION IMMUNOLOGY

30問 • 2年前

Yves Laure Pimentel · 38問 · 2年前

2. LYMPHOID ORGANS

2. LYMPHOID ORGANS

38問 • 2年前

Yves Laure Pimentel · 48問 · 2年前

3. CLUSTER OF DIFFERENTIATION

3. CLUSTER OF DIFFERENTIATION

48問 • 2年前

Yves Laure Pimentel · 35問 · 2年前

4. T-CELL DIFFERENTIATION

4. T-CELL DIFFERENTIATION

35問 • 2年前

Yves Laure Pimentel · 18問 · 2年前

5. T CELL IMMUNODEFICIENCIES

5. T CELL IMMUNODEFICIENCIES

18問 • 2年前

Yves Laure Pimentel · 44問 · 2年前

6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

44問 • 2年前

Yves Laure Pimentel · 23問 · 2年前

7. B CELL IMMUNODEFICIENCIES

7. B CELL IMMUNODEFICIENCIES

23問 • 2年前

Yves Laure Pimentel · 34問 · 2年前

8. COMBINED T CELL AND B CELL DEFICIENCIES

8. COMBINED T CELL AND B CELL DEFICIENCIES

34問 • 2年前

Yves Laure Pimentel · 12問 · 2年前

9. COMPARISON OF T AND B CELLS

9. COMPARISON OF T AND B CELLS

12問 • 2年前

Yves Laure Pimentel · 16問 · 2年前

10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

16問 • 2年前

Yves Laure Pimentel · 15問 · 2年前

11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

15問 • 2年前

Yves Laure Pimentel · 79問 · 2年前

12. ANTIBODY

12. ANTIBODY

79問 • 2年前

Yves Laure Pimentel · 97問 · 2年前

13. TYPES OF ANTIBODIES

13. TYPES OF ANTIBODIES

97問 • 2年前

Yves Laure Pimentel · 11問 · 2年前

14. MONOCLONAL ANTIBODIES

14. MONOCLONAL ANTIBODIES

11問 • 2年前

Yves Laure Pimentel · 23問 · 2年前

1. INTERLEUKINS

1. INTERLEUKINS

23問 • 2年前

Yves Laure Pimentel · 28問 · 2年前

2. INTERFERONS

2. INTERFERONS

28問 • 2年前

Yves Laure Pimentel · 8問 · 2年前

3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

8問 • 2年前

Yves Laure Pimentel · 19問 · 2年前

4. COMPLEMENT SYSTEM

4. COMPLEMENT SYSTEM

19問 • 2年前

Yves Laure Pimentel · 76問 · 2年前

15. COMPLEMENT SYSTEM

15. COMPLEMENT SYSTEM

76問 • 2年前

Yves Laure Pimentel · 21問 · 2年前

16. SYSTEM CONTROLS/COMPLEMENT REGULATION

16. SYSTEM CONTROLS/COMPLEMENT REGULATION

21問 • 2年前

Yves Laure Pimentel · 29問 · 2年前

17. COMPLEMENT AND DISEASE STATES

17. COMPLEMENT AND DISEASE STATES

29問 • 2年前

Yves Laure Pimentel · 19問 · 2年前

18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

19問 • 2年前

Yves Laure Pimentel · 22問 · 2年前

19. CYTOKINES

19. CYTOKINES

22問 • 2年前

Yves Laure Pimentel · 24問 · 2年前

20. INTERLEUKINS

20. INTERLEUKINS

24問 • 2年前

Yves Laure Pimentel · 21問 · 2年前

21. INTERFERONS, TNF, TGF, CHEMOKINE

21. INTERFERONS, TNF, TGF, CHEMOKINE

21問 • 2年前

Yves Laure Pimentel · 54問 · 2年前

1. SERO

1. SERO

54問 • 2年前

Yves Laure Pimentel · 38問 · 2年前

2. PRECIPITATION

2. PRECIPITATION

38問 • 2年前

Yves Laure Pimentel · 17問 · 2年前

3. PASSIVE IMMUNODIFFUSION

3. PASSIVE IMMUNODIFFUSION

17問 • 2年前

Yves Laure Pimentel · 15問 · 2年前

4. OUCHTERLONY

4. OUCHTERLONY

15問 • 2年前

Yves Laure Pimentel · 9問 · 2年前

5. ELECTROPHORETIC TECHNIQUE

5. ELECTROPHORETIC TECHNIQUE

9問 • 2年前

Yves Laure Pimentel · 11問 · 2年前

6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

11問 • 2年前

Yves Laure Pimentel · 29問 · 2年前

7. IMMUNOFIXATION ELECTROPHORESIS

7. IMMUNOFIXATION ELECTROPHORESIS

29問 • 2年前